BioCryst Pharmaceuticals | Crediti Commerciali





Crediti Commerciali Cambiamento Data
Alnylam Pharmaceuticals USD 964.77M 397.66M 2025-09
BioCryst Pharmaceuticals USD 79.07M 6.61M 2024-12
Chugai Pharma JPY 443.11B 89.26B 2025-12
Daiichi Sankyo JPY 695.95B 79.1B 2025-12
DBV Technologies USD 15.97M 279K 2025-09
Enanta Pharmaceuticals USD 40.16M 1.52M 2024-12
Gilead Sciences USD 5.1B 314M 2025-09
GlaxoSmithKline GBP 7.76B 545M 2025-12
Glaxosmithkline GBP 11.16B 3.46B 2025-09
Incyte USD 1.02B 128.52M 2025-12
Ionis Pharmaceuticals USD 24.61M 27.97M 2025-09
Karyopharm Therapeutics USD 31.78M 6.82M 2024-09
Neurocrine Biosciences USD 728M 132.3M 2025-09
Novavax USD 94.96M 62.81M 2024-09
PTC Therapeutics USD 203.07M 6.94M 2025-09
Regeneron Pharmaceuticals USD 5.74B 54M 2025-12
Roche Holding CHF 11.9B 460M 2025-12
Sarepta Therapeutics USD 395.74M 213.86M 2025-09
Ultragenyx Pharmaceutical USD 112.54M 11.92M 2025-09
Vertex Pharmaceuticals USD 1.95B 52.9M 2025-09


BioCryst Pharmaceuticals Crediti Commerciali - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Feb 2026.